Irbesartan And Hydrochlorothiazide
Irbesartan + Hydrochlorothiazide
6 active makers
soon
soon
soon
soon
US acquisition costNADAC · per unit
Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Irbesartan + Hydrochlorothiazide
Average across 8 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Alembic Pharmaceuticals Limited | generic | 20 | SUPPLYING |
| Bryant Ranch Prepack | repackager | 8 | SUPPLYING |
| Solco Healthcare US, LLC | unknown | 6 | SUPPLYING |
| Hikma Pharmaceuticals USA Inc. | generic | 4 | SUPPLYING |
| Proficient Rx LP | repackager | 3 | SUPPLYING |
| REMEDYREPACK INC. | repackager | 2 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Prinston Pharmaceutical Inc — Nationwide
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Prinston Pharmaceutical Inc — Nationwide
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Prinston Pharmaceutical Inc — Nationwide
CGMP Deviations: FDA lab confirmed presence an impurity, N-nitrosodimethylamine (NDEA) contained in the API used to manufacture the product above the interim acceptable daily intake level of 0.083 parts per million. — Recalling firm: Prinston Pharmaceutical Inc — Nationwide
Labeling: Incorrect or Missing Lot and/or Exp Date: Incorrect lot number, 327B160012, appears on the case label, the correct lot number, 327B16002 appears on the immediate container. — Recalling firm: Prinston Pharmaceutical Inc — Nationwide